Alpha-1 Antitrypsin Deficiency Treatment Market Global Trends, Size, Segments and Growth Forecast to 2027
The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency. Registering a CAGR of 10.50%, the Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to grow from USD 1,464.1 Million in 2018 to USD 2,914.7 Million. As of July 2019, 3.4 million people are affected by alpha-1 antitrypsin deficiency worldwide. The disorder is found to affect populations in all the regions of the world. The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment prolactin market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government